ORLANDO — A novel triple-agent combination of carfilzomib, dexamethasone and daratumumab outperformed carfilzomib plus dexamethasone in terms of PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to results of the randomized phase 3 CANDOR trial presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.

The three-drug regimen also conferred a higher rate of minimal residual disease (MRD)-negative complete response than carfilzomib and dexamethasone with a similar overall safety profile; however, the triplet therapy appeared associated with higher rates of serious adverse events and five treatment-related deaths.